Back to top
more

CureVac (CVAC)

(Delayed Data from NSDQ)

$2.33 USD

2.33
837,590

+0.02 (0.87%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CVAC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for CureVac NV falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 527 916 1,514 -99,999
Receivables NA 7 21 1 NA
Notes Receivable NA 0 0 0 NA
Inventories NA 25 63 17 NA
Other Current Assets NA 56 55 56 NA
Total Current Assets NA 615 1,055 1,588 NA
Net Property & Equipment NA 209 189 76 NA
Investments & Advances NA 0 0 0 NA
Other Non-Current Assets NA 0 0 0 NA
Deferred Charges NA 1 3 1 NA
Intangibles NA 33 15 16 NA
Deposits & Other Assets NA 2 2 7 NA
Total Assets NA 907 1,300 1,726 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 NA
Accounts Payable NA 77 143 25 NA
Current Portion Long-Term Debt NA 0 0 0 NA
Current Portion Capital Leases NA 5 4 4 NA
Accrued Expenses NA 0 0 0 NA
Income Taxes Payable NA 1 1 0 NA
Other Current Liabilities NA 81 253 254 NA
Total Current Liabilities NA 165 401 283 NA
Mortgages NA 0 0 0 NA
Deferred Taxes/Income NA 0 0 0 NA
Convertible Debt NA 0 0 0 NA
Long-Term Debt NA 0 0 0 NA
Non-Current Capital Leases NA 39 29 31 NA
Other Non-Current Liabilities NA 141 97 600 NA
Minority Interest (Liabilities) NA 0 0 0 NA
Total Liabilities NA 345 527 914 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 NA
Common Stock (Par) NA 25 25 25 NA
Capital Surplus NA 1,915 1,940 1,525 NA
Retained Earnings NA -1,376 -1,186 -737 NA
Other Equity NA 0 0 0 NA
Treasury Stock NA 2 7 0 NA
Total Shareholder's Equity NA 562 773 813 NA
Total Liabilities & Shareholder's Equity NA 907 1,300 1,726 NA
Total Common Equity 0 562 773 813 0
Shares Outstanding 223.80 194.90 187.10 181.10 NA
Book Value Per Share 0.00 2.88 4.13 4.49 0.00

Fiscal Year End for CureVac NV falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 509 592 666
Receivables NA NA 11 7 4
Notes Receivable NA NA 0 0 0
Inventories NA NA 25 24 26
Other Current Assets NA NA 39 34 41
Total Current Assets NA NA 584 658 737
Net Property & Equipment NA NA 249 239 226
Investments & Advances NA NA 0 0 0
Other Non-Current Assets NA NA 0 0 0
Deferred Charges NA NA 1 1 1
Intangibles NA NA 33 35 33
Deposits & Other Assets NA NA 2 2 2
Total Assets NA NA 917 981 1,045
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA 0 0 0
Accounts Payable NA NA 14 15 16
Current Portion Long-Term Debt NA NA 0 0 0
Current Portion Capital Leases NA NA 6 6 5
Accrued Expenses NA NA 0 0 0
Income Taxes Payable NA NA 1 1 1
Other Current Liabilities NA NA 144 149 75
Total Current Liabilities NA NA 164 170 97
Mortgages NA NA 0 0 0
Deferred Taxes/Income NA NA 0 0 0
Convertible Debt NA NA 0 0 0
Long-Term Debt NA NA 0 0 0
Non-Current Capital Leases NA NA 40 38 39
Other Non-Current Liabilities NA 58 64 144
Minority Interest (Liabilities) NA NA 0 0 0
Total Liabilities NA NA 262 273 279
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA 0 0 0
Common Stock (Par) NA NA 29 29 29
Capital Surplus NA NA 2,237 2,239 2,201
Retained Earnings NA NA -1,610 -1,560 -1,463
Other Equity NA NA 0 0 0
Treasury Stock NA NA 0 0 0
Total Shareholder's Equity NA NA 656 708 766
Total Liabilities & Shareholder's Equity NA NA 917 981 1,045
Total Common Equity 0 0 656 708 766
Shares Outstanding 223.80 223.80 223.80 223.80 223.80
Book Value Per Share 0.00 0.00 2.93 3.16 3.42